https://news.yale.edu/2026/04/02/zebrafish-reveal-new-insights-biology-autism?utm_source=YaleToday&utm_medium=email&utm_campaign=YT_YaleToday-Faculty_4-7-2026 QT{{” Here, we leverage the strengths of zebrafish as a scalable in vivo system to screen 520 US FDA-approved drugs and establish a database of their effects on sensory processing and arousal behaviors. Using this database, we nominate pharmacological candidates relevant to specific ASD genes or gene subgroups. “}}
Jamadagni, P., Dai, Y., Liu, Y., Mendes, H. W., Pruitt, A., Khan, S., Yang, L., Huang, T., Huang, X., Deans, P. J. M., Balafkan, N., Zhao, D., Xu, G., Liu, Y., Li, N., Wu, W., Fitzpatrick, S. E., Neelakantan, U., Chen, T., . . . Hoffman, E. J. (2026). Pharmaco-behavioral profiling identifies suppressors of autism gene–associated phenotypes in zebrafish. Proceedings of the National Academy of Sciences, 123(12), e2518846123. https://doi.org/10.1073/pnas.2518846123
linkstream2 microblog 